The World Health Organization has prequalified Coartem Baby, the first and only antimalarial for babies. Novartis developed this combination drug in partnership with Medicines for Malaria Venture.
This month, the World Health Organization released new guidelines on the ethics and governance of LLMs in healthcare. Reactions from the leaders of healthcare AI companies have been mainly positive. However, one leader pointed out that fear or the risks associated with LLMs shouldn't hinder innovation, and another noted that the guidance may have failed to mention a major topic.
How to turn analytics into actual policy outcomes.
The new Covid-19 variant, named Omicron, has mutations that could help it evade antibodies produced by the immune system. Scientists are conducting lab tests to better understand this new variant and pharmaceutical companies are testing how existing vaccines, as well as those in development, measure up the new mutations.
The new tests can open a window into the duration of immunity and to the antibody levels needed to sustain it. But first, a universal standard is needed to ensure results are comparable between tests.
The partners pooled results from two trials and two different dosing regimens, one appearing to be more effective than the other. They hope to produce 3 billion doses in 2021 with an emphasis on serving poorer countries.
The WHO's REACT Working Group published an analysis of seven trials of dexamethasone, hydrocortisone and methylprednisolone in the Journal of the American Medical Association Wednesday, finding a lower rate of all-cause mortality at 28 days among critically ill patients receiving the drugs.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Data from a suspended Phase III trial in China of Gilead's remdesivir produced a negative result. An executive cautioned that the trial's low enrollment meant it had insufficient statistical power to draw any conclusions, but an analyst reiterated the view that the drug's pandemic role is overestimated.
The agency is expected to rule on the vaccine by March 14 of next year. The company has shipped nearly a quarter of 1 million doses of the vaccine to the WHO for countries facing outbreaks like the Democratic Republic of the Congo.
Also, The World Health Organization has posted a final version of its proposed biologics naming policy, and new research suggests that the financial burden that cancer care puts on many people contributes to lower survival rates.
Theories from economics could play a role in how we combat antibiotic resistance.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Despite being neglected for several years, a surprisingly effective cholera vaccine is emerging as an inexpensive solution to an epidemic-level problem, a new Lancet study finds.
The WHO has released regulations on things to not include when naming new disease, such as reference to people, animals and places.
The World Health Organization is clarifying the dos and don'ts of how we name emerging diseases.
TOP STORIES The World Health Organization has called for the release of clinical trial results for all drugs, vaccines and medical devices in an effort to prevent the withholding of data. The U.S. Senate voted to pass the “Doc Fix Bill,” repealing Medicare’s sustainable growth rate formula for paying doctors. We think Obama will sign […]
People can do their best to protect themselves from things like hepatitis and HIV by being responsible and aware, but when doctors reuse syringes, all efforts can fall by the wayside. Situations like this have prompted a global campaign from the World Health Organization this week. As NPR reported Tuesday, an 82-year-old celibate Buddhist abbot […]